Christian Chijioke Amah

Dr. Christian Chijioke Amah

University of Nigeria, Nsukka, Enugu, Nigeria
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2021 in Clinical Phytoscience
Verified
Journal Article
Open access
PDF file
OEOsmond Chukwuma Enechi
Osmond Chukwuma Enechi
CAChristian Chijioke Amah
Christian Chijioke Amah
IOInnocent Okagu
Innocent Okagu
POPamela Chidinma Ononiwu
Pamela Chidinma Ononiwu
ANAlice Chinwendu Nweke
Alice Chinwendu Nweke
BCBlessing Chiamaka Chukwurah
Blessing Chiamaka Chukwurah
Background: Malaria has continued to be a threat to man and his wellbeing, especially Africans and Asians. New antimalarial drugs are urgently needed to mitigate malaria treatment failure due to resistant Plasmodium species. Medicinal plants used by indigenous Nigerians for treating fever and malaria such as Sida acuta Burm.f. (Malvaceae) could be a promising source of lead compounds for developing new generations of antimalarial drugs. The effects of ethanol extract of S. acuta leaves (EESAL) on malaria parasitemia, haematological and biochemical status of P. berghei-infected mice were investigated, using the 4-day curative test. Methodology: EESAL was prepared by maceration method. The phyto-constituents and acute toxicity profile of the extract were evaluated using standard protocols. In addition, malaria parasitemia and chemo-suppression, and indicators of haematological and biochemical status of P. berghei-infected mice treated with EESAL were assessed. Results: At 200, 400 and 600 mg/kg/d b.w., p.o doses for 4 consecutive days, EESAL significantly (p < 0.05) decreased parasitaemia and suppressed malaria parasite by 89.64%, 95.95% and 97.38%, respectively comparable to negative control. The reduction in percentage malaria parasitemia by EESAL is comparable to Artemether (140 mg/kg/d b.w., p.o) used as standard antimalarial drug in this study. The packed cell volume (PCV), haemoglobin (Hb) concentration, and red blood cell (RBC) and white blood cell (WBC) counts of negative control are significantly (p < 0.05) higher than normal control. However, parasitized-EESAL-treated mice have significantly (p < 0.05) higher PCV value, Hb concentration and RBC and WBC counts than negative control. Similarly, treatment of parasitized mice with EESAL restored some indicators of the antioxidant, lipid peroxidation, lipid profile and liver status altered by malaria. In addition, EESAL was tolerable up to 5000 mg/kg b.w., p.o. Conclusion: These results indicate that the EESAL possesses antimalarial activity and normalizes alterations in haematological and biochemical status of malaria-infected mice.

4 April 2022 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
CAChristian Chijioke Amah
Christian Chijioke Amah
PJParker Joshua
Parker Joshua
DEDaniel Ekpo
Daniel Ekpo
JOJacob Ikechukwu Okoro
Jacob Ikechukwu Okoro
RARita Asomadu
Rita Asomadu
AOArome Solomon Odiba
Arome Solomon Odiba

1 July 2021 in Scientific African
Verified
Journal Article
Open access
OEOsmond Chukwuma Enechi
Osmond Chukwuma Enechi
IOInnocent Uzochukwu Okagu
Innocent Uzochukwu Okagu
CAChristian Chijioke Amah
Christian Chijioke Amah
POPamela Chidinma Ononiwu
Pamela Chidinma Ononiwu
JIJohn Francis Igwe
John Francis Igwe
COChianaza Rosemary Onyekaozulu
Chianaza Rosemary Onyekaozulu

1 February 2021 in Comparative Clinical Pathology
Verified
Journal Article
Closed access
PDF file
CAChristian Chijioke Amah
Christian Chijioke Amah
OEOsmund Chukwuma Enechi
Osmund Chukwuma Enechi
DEDaniel Ekpo
Daniel Ekpo
IOInnocent Okagu
Innocent Okagu
COChidinma Ononiwu
Chidinma Ononiwu
PJParker Joshua
Parker Joshua

18 November 2024 in Laboratory Animal Research
Verified
Journal Article
Open access
PDF file
COChidinma Pamela Ononiwu
Chidinma Pamela Ononiwu
PJParker Joshua
Parker Joshua
CAChristian Chijioke Amah
Christian Chijioke Amah
RARita Asomadu
Rita Asomadu
EOEkezie Matthew Okorigwe
Ekezie Matthew Okorigwe
OAOnyinyechi Becky Adiele
Onyinyechi Becky Adiele
Background: Myocardial Infarction still persists as the most prevalent cardiovascular disease and is a top cause of morbidity and mortality in doxorubicin treated cancer patients. This study evaluated the prophylactic effect of the ethanol root bark extract of Cleistopholis patens (ERBECP) against doxorubicin-induced myocardial infarction in wistar rats. Extraction, preliminary phytochemical analysis, acute toxicity study and body weight (b.w.) of ERBECP were achieved using standard methods. Phyto-constituents in ERBECP were indentified using Gas Chromatography-Mass Spectrometry (GC–MS) technique. Thirty (30) male albino Wistar rats of average b.w. ranging between 100 and 130 g were divided into six groups of five rats each. Groups I, II and III served as normal, doxorubicin (DOX) and standard (Vasoprin 150 mg/kg b.w) controls respectively, while groups IV, V and VI were orally pre-treated with the extract (200, 400 and 600 mg/kgb.w) for two weeks prior to intraperitoneal induction of cardiotoxicity with DOX (20 mg/kg bw) on day 14. Results: Disturbances in serum cardiac function bio-markers such as; Cardiac Troponin-I (CTnI), Creatine Kinase (CK), Lactate Dehydrogenase (LDH), Aspartate aminotransferase (AST), Alanine aminotransferase (ALT). Lipid profile markers such as; Total cholesterol (TC), Triacylglycerol (TAG), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL). Oxidative stress markers such as; Malondialdehyde (MDA), Superoxide Dismutase (SOD), Catalase (CAT), Glutathione (GSH) confirmed the induction of myocardial infarction. Histological assessment of heart tissues was performed to validate biochemical results. The GC–MS analysis of ERBECP identified a total of 69 compounds. Safety profile of the aqueous extract was safe for the animals up to the highest dose of 5000 mg/kg b.w. Pre-treatment of DOX group with ERBECP could significantly increase the b.w. compared to the DOX-treated group during the experimental period of 2 weeks. There were significant (p < 0.05) alterations in the levels of CTnI, CK, LDH, AST, ALT and lipid profile indices in the DOX control rats. Also, significant (p < 0.05) increase was observed in MDA and decrease in SOD, CAT and GSH in the DOX control rats. However, administration of the extract significantly (p < 0.05) normalized these alterations and reversed the architectural changes in the heart. The 69 compounds were screened against the target protein (CBR1); we identified seven hits based on the docking score and interactions with the active site residues. All the C. patens constituents had MW (g/mol) less than 500, HBA < 10 and HBD not more than 5. Apart, 9-Octadecenoic acid (Z)-, 2,3-dihydroxy propyl ester and Estra-1,3,5(10)-trien-17. beta. -ol, all the constituents had LD50 lower than 2000 mg/kg. Conclusions: The findings reveals ERBECP demonstrated promising potential and can be exploited in the development novel cardiac therapeutic agents.

12 June 2026 in BMC Complementary Medicine and Therapies
Verified
Journal Article
Open access
JOJuliet Nwamaka Ozioko-Agbo
Juliet Nwamaka Ozioko-Agbo
DEDaniel Ekpo
Daniel Ekpo
CAChristian Chijioke Amah
Christian Chijioke Amah
MCMichael Chinedu Chukwu
Michael Chinedu Chukwu
PJParker Joshua
Parker Joshua
LELawrence Uchenna Sunday Ezeanyika
Lawrence Uchenna Sunday Ezeanyika
Annona muricata L., known for its medicinal properties, has been explored for its potential in treating benign prostatic hyperplasia (BPH). While previous studies have noted its numerous health benefits, this research evaluated the therapeutic potential of seed extract of Annona muricata (SEAM) against BPH in rats by exploring in vivo and in silico approaches. SEAM extraction, phytochemical analysis, in vitro antioxidant activities, and acute toxicity were achieved using standard methods. Thirty male Wistar rats (weight: 158-192 g) were randomly divided into six groups of five rats each. The groups were assigned as follows: (1) normal control, (2) negative control, (3) positive control, and (4-6) experimental groups. BPH was induced in rats of groups (2-6) by subcutaneous injection of 3 mg/kg body weight (b.w) testosterone for 28 days, followed by daily oral treatment with 5 mg/kg b.w. Finasteride, 200, 400 and 600 mg/kg b.w SEAM, respectively for 21 days. The effect of SEAM treatment on changes in rats' biochemical, hematological, and histological indices was assessed. Extraction of 3000 g of A. muricata seeds yielded 255.6 g SEAM. GC-MS analysis of SEAM revealed flavonoids, alkaloids, polyphenols, and saponins. SEAM exhibited strong radical scavenging activity in vitro. BPH induction in rats triggered significant (p < 0.05) alterations in some biochemical, hematological and histological profiles of test rats. Notably, SEAM significantly (p <0.05) normalized altered levels of prostate-specific antigen, testosterone, antioxidant enzymes, and hematological parameters of treated rats, and is comparable to the standard drug, Finasteride. Molecular docking studies revealed strong binding interactions between SEAM phytochemicals and 5-alpha reductase, suggesting inhibition of this enzyme as a key mechanism of SEAM action. Our study not only confirms the therapeutic potential of SEAM in BPH management but also provides insights into novel biochemical pathways and molecular interactions. These findings indicate that SEAM possess significant anti-BPH property through antioxidant activity and 5-alpha reductase inhibitory activity, providing scientific validation for its potential as a natural remedy for BPH, and setting the stage for further mechanistic studies and clinical trials.